This study aims to prevent infection in people living with people who have been confirmed to have COVID-19 symptoms.
Pfizer announced on Monday that it has reached the mid-to-late part of a large study to find oral antivirals against COVID-19. Its purpose is to prevent the transmission of people exposed to the virus.
In a statement from a pharmaceutical company, the study included 2,660 healthy adults over the age of 18 living in the same household as those with COVID-19 symptoms.
This treatment combines a new oral antiviral candidate, PF-07321332, with a low-dose ritonavir.
According to the National Institutes of Health’s HIV.gov website, ritonavir was approved by the US Food and Drug Administration in 1999 for the treatment of HIV in adults and children over a month. Recently, ritonavir is most commonly used to improve the performance of other HIV drugs.
Participants will participate in a double-blind, double-dummy study divided into three groups. Participants will take the PF-07321332 / ritonavir combination for 10 days, the placebo for 10 days, or the drug combination for 5 days, followed by the placebo for 5 days.
“The main purpose is to assess the safety and efficacy of the confirmed SARS-CoV-2 infection and its symptoms by day 14”, said Pfizer.
Dr. Sujasa Lady of Northside Hospital in Atlanta said it reminds us of another type of treatment, Tamiflu.
“We give it to people who are exposed to the flu and early in the diagnosis to prevent them from getting very ill,” she said.
This is Phase 2/3 of the clinical trial. Pfizer said Phase 1 “showed that PF-07321332 was safe and well tolerated.”
The NIH said the investigation is expected to be completed by December 25.
Reuters reports that Pfizer is conducting another study of PF-07321332 in adult COVID-19 patients who are symptomatic and not hospitalized. Merck is also reported to be in late-stage trials of its own experimental drug to prevent COVID-19 infection.
Remdesivir is the only FDA-approved antiviral treatment.
Pfizer’s COVID-19 oral antiviral drug enters late-stage study
Source link Pfizer’s COVID-19 oral antiviral drug enters late-stage study